Results 51 to 60 of about 420,437 (312)

CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer

Cell Death and Disease, 2022
Herein, Liu and colleagues show that CD4+ T cells in cytokine-induced killer (CIK) cells are required to enhance the clinical efficacy of CIK therapy. In addition, CD4+ T cells help via IL-17A production is critical to restoring the function of CD8+/CD3 ...
Shaochuan Liu, Yuan Meng, Liang Liu, Yingge Lv, Wenwen Yu, Ting Liu, Limei Wang, Di Mu, Qiuru Zhou, Min Liu, Yulin Ren, Dong Zhang, Baihui Li, Qian Sun, Xiubao Ren   +14 more
doaj   +1 more source

Enhancing cytokine-induced killer cell therapy of multiple myeloma [PDF]

Experimental Hematology, 2013
Cytokine-induced killer (CIK) cells are in clinical testing against various tumor types, including multiple myeloma. In this study, we show that CIK cells have activity against subcutaneous and disseminated models of human myeloma (KAS-6/1), which can be enhanced by infecting the CIK cells with an oncolytic measles virus (MV) or by pretreating the ...
Chunsheng, Liu, Lukkana, Suksanpaisan, Yun-Wen, Chen, Stephen J, Russell, Kah-Whye, Peng   +4 more
openaire   +2 more sources

Alopecia areata: a multifactorial autoimmune condition [PDF]

, 2019
Alopecia areata is an autoimmune disease that results in non-scarring hair loss, and it is clinically characterised by small patches of baldness on the scalp and/or around the body. It can later progress to total loss of scalp hair (Alopecia totalis) and/
Butcher, John P., Henriquez, Fiona L., Reid, Stuart, Simakou, Teontor   +3 more
core   +1 more source

Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy

Haematologica, 2013
Invariant natural killer T cells recognize glycolipid antigens such as α-galactosylceramide presented by CD1d. In preclinical models of B-cell malignancies, α-galactosylceramide is an adjuvant to tumor vaccination, enhancing tumor-specific T-cell ...
Robert Weinkove, Collin R. Brooks, John M. Carter, Ian F. Hermans, Franca Ronchese   +4 more
doaj   +1 more source

NCR+ ILC3 maintain larger STAT4 reservoir via T-BET to regulate type 1 features upon IL-23 stimulation in mice [PDF]

, 2018
Innate lymphoid cells (ILCs) producing IL-22 and/or IL-17, designated as ILC3, comprise a heterogeneous subset of cells involved in regulation of gut barrier homeostasis and inflammation.
Kanno, Yuka, Mikami, Yohei, O'Shea, John J, Santoni, Angela, SCARNO, GIANLUCA, Sciumè, Giuseppe, Shih, Han-Yu, Zitti, Beatrice   +7 more
core   +1 more source

Cytokine-Induced Killer Cells Eradicate Bone and Soft-Tissue Sarcomas [PDF]

Cancer Research, 2014
AbstractUnresectable metastatic bone sarcoma and soft-tissue sarcomas (STS) are incurable due to the inability to eradicate chemoresistant cancer stem–like cells (sCSC) that are likely responsible for relapses and drug resistance. In this study, we investigated the preclinical activity of patient-derived cytokine-induced killer (CIK) cells against ...
SANGIOLO, Dario, Mesiano G, Gammaitoni L, Leuci V, Todorovic M, Giraudo L, Cammarata C, Dell'aglio C, D'Ambrosio L, Pisacane A, Sarotto I, Miano S, FERRERO, Ivana, Carnevale Schianca F, PIGNOCHINO, YMERA, Sassi F, BERTOTTI, Andrea, PIACIBELLO, Vanda, Fagioli F, AGLIETTA, Massimo, Grignani G.   +20 more
openaire   +4 more sources

Immune cells and preterm labour:do invariant NKT cells hold the key? [PDF]

, 2015
We have developed our original made-to-measure (M2M) algorithm, PRIMAL, with the aim of modelling the Galactic disc from upcoming Gaia data. From a Milky Way like N-body disc galaxy simulation, we have created mock Gaia data using M0III stars as tracers,
Rinaldi, S F, Rossi, A G, Saunders, Philippa, Norman, J E   +3 more
core   +3 more sources

Rapid response of advanced squamous non-small cell lung cancer with thrombocytopenia after first-line treatment with pembrolizumab plus autologous cytokine-induced killer cells

Frontiers in Immunology, 2015
We present the first clinical evidence of advanced squamous non-small cell lung cancer with severe thrombocytopenia showing dramatic improvement after first-line treatment with pembrolizumab plus cytokine-induced killer cells.
Zhenzhen eHui, Xinwei eZhang, Baozhu eRen, Runmei eLi, Xiubao eRen   +4 more
doaj   +1 more source

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

Clinical & Translational Immunology, 2021
Objectives Although axitinib has achieved a preferable response rate for advanced renal cell carcinoma (RCC), patient survival remains unsatisfactory. In this study, we evaluated the efficacy and safety of a combination treatment of axitinib and a low ...
Meng‐Jia Song, Qiu‐Zhong Pan, Ya Ding, Jianxiong Zeng, Pei Dong, Jing‐Jing Zhao, Yan Tang, Jingjing Li, Zhiling Zhang, Junyi He, Jieying Yang, Yue Huang, Ruiqing Peng, Qi‐Jing Wang, Jia‐Mei Gu, Jia He, Yong‐Qiang Li, Shi‐Ping Chen, Rongxing Huang, Zi‐Qi Zhou, Chaopin Yang, Yulong Han, Hao Chen, Heping Liu, Shangzhou Xia, Yang Wan, De‐Sheng Weng, Liming Xia, Fang‐Jian Zhou, Jian‐Chuan Xia   +29 more
doaj   +1 more source

Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer

Frontiers in Immunology, 2022
Breast cancer is one of the most common cancers in women. Triple-negative breast cancer (TNBC) has a significantly worse prognosis due to the lack of endocrine receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal ...
Xinyi Yang, Xinyi Yang, Desheng Weng, Desheng Weng, Qiuzhong Pan, Qiuzhong Pan, Tong Xiang, Tong Xiang, Chaopin Yang, Chaopin Yang, Zhengrong Wu, Minxing Li, Minxing Li, Songzuo Xie, Songzuo Xie, Yan Tang, Yan Tang, Jianchuan Xia, Jianchuan Xia, Jingjing Zhao, Jingjing Zhao   +20 more
doaj   +1 more source